Navigating a complex benefits landscape
The past decade has witnessed significant improvements in the ability of the medical profession to treat cancer successfully and cancer survival rates are now at an all time high due to earlier detection and more advanced therapy.
As the latest treatments and drugs, especially those based on monoclonal antibodies, are very expensive, insurers are offering lots of different levels of cover for cancer.
We can help you navigate the complex pathways to supporting scheme members with cancer. Tools such as our Cancer Modeller will project future benefit costs around monoclonal antibody/cancer drug treatment to help you to make informed, measured decisions.
We’ve written an advice guide series on the current status of cancer care in the UK and the innovations paving the way for a new era in cancer management. Read them here.